CSPC Pharmaceutical Group revenue and financials
$9.87Change from previous close: −1.30%Absolute change: −$0.13
In the fiscal year ended December 2025, CSPC Pharmaceutical Group reported revenue of ¥26.01B (−10.35% year over year). Net income was ¥3.88B, a net margin of 14.9%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- −10.35%
- 2025 vs 2024
- Net income growth
- −10.30%
- 2025 vs 2024
- Net margin
- 14.9%
- 2024: 14.9%
Financial data
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | Q2 2026 | Q4 2025 | Q2 2025 |
|---|---|---|---|
| Total assets | 56,022 | 46,698 | 46,002 |
| Current assets | 30,855 | 22,251 | 22,610 |
| Cash and equivalents | 10,002 | 6,090 | 7,571 |
| Short-term investments | 8,545 | 2,776 | 2,133 |
| Inventory | 2,962 | 3,091 | 2,871 |
| Net property, plant and equipment | 14,205 | 14,046 | 13,631 |
| Goodwill | 236 | 235 | 235 |
| Other intangible assets | 2,985 | 2,775 | 2,655 |
| Long-term investments | 1,178 | 1,466 | 1,523 |
| Current liabilities | 14,424 | 10,178 | 10,113 |
| Accounts payable | 2,705 | 2,976 | 2,288 |
| Long-term debt | 274 | — | — |
| Total debt | 652 | 641 | 495 |
| Total liabilities | 16,590 | 12,148 | 11,138 |
| Total equity (incl. minority) | 39,431 | 34,550 | 34,864 |
| Retained earnings | 29,090 | 24,475 | 24,512 |
| Minority interest | 1,807 | 1,372 | 1,614 |